Clinical Trial Update: Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating telmisartan for reducing intramyocellular lipids in metabolic syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Syndrome

Drugs mentioned

• Telmisartan (Telmisartan)

Snippet

Sponsor: McMaster University | Conditions: Metabolic Syndrome X | Phase 3 | Status: COMPLETED